Sign up for the QMED & MD+DI Daily newsletter.
Does Medtech Have an Appetite for M&A?—Boston Scientific
Boston Scientific's Commentary on M&A"Near term, our capital allocation priorities are to prepay debt, manage our contingencies and pursue tuck-in M&A."
May 13, 2016
1 Min Read
Boston Scientific's Commentary on M&A
"Near term, our capital allocation priorities are to prepay debt, manage our contingencies, and pursue tuck-in M&A." Daniel Brennan, Boston Scientific CFO, according to a Seeking Alpha transcript of the company's first quarter earnings call |
|
Get inspired to innovate in medtech at the MD&M East Conference, June 14-16, in New York City. |
[Image courtesy of STUART MILES/FREEDIGITALPHOTOS.NET]
You May Also Like
.png?width=300&auto=webp&quality=80&disable=upscale)
